In an industry where 90 percent of drug candidates fail before reaching the market, a handful of startups are betting everything on AI to beat the odds.

Businesses in highly-regulated industries like financial services, insurance, pharmaceuticals, and health care are increasingly turning to AI-powered tools to streamline complex and sensitive tasks. Conversational AI-driven interfaces are helping hospitals to track the location and delivery of a patient’s time-sensitive cancer drugs. Generative AI chatbots are helping insurance customers answer questions and solve problems. And agentic AI systems are emerging to support financial services customers in making complex financial planning and budgeting decisions.  “Over the last 15 years of digital transformation, the orientation in many regulated sectors has been to look at digital technologies as a place to provide more cost-effective and meaningful customer experience and divert customers from higher-cost, more complex channels of service,” says Peter Neufeld, who leads the EY Studio+ digital and customer experience capability at EY for financial services companies in the UK, Europe, the Middle East, and Africa.  DOWNLOAD THE FULL REPORT For many, the “last mile” of the end-to-end customer journey can present a challenge. Services at this stage often involve much more complex interactions than the usual app or self-service portal can handle. This could be dealing with a challenging health diagnosis, addressing late mortgage payments, applying for government benefits, or understanding the lifestyle you can afford in retirement. “When we get into these more complex service needs, there’s a real bias toward human interaction,” says Neufeld. “We want to speak to someone, we want to understand whether we’re making a good decision, or we might want alternative views and perspectives.”  But these high-cost, high-touch interactions can be less than satisfying for customers when handled through a call center if, for example, technical systems are outdated or data sources are disconnected. Those kinds of problems ultimately lead to the possibility of complaints and lost business. Good customer experience is critical for the bottom line. Customers are 3.8 times more likely to make return purchases after a successful experience than after an unsuccessful one, according to Qualtrics. Intuitive AI-driven systems— supported by robust data infrastructure that can efficiently access and share information in real time— can boost the customer experience, even in complex or sensitive situations.  Download the full report. This content was produced by Insights, the custom content arm of MIT Technology Review. It was not written by MIT Technology Review’s editorial staff. This content was researched, designed, and written entirely by human writers, editors, analysts, and illustrators. This includes the writing of surveys and collection of data for surveys. AI tools that may have been used were limited to secondary production processes that passed thorough human review.

President Donald Trump has disrupted global trade and roiled markets in an effort to bring manufacturing jobs back to the U.S. Some of his top tech allies, however, have backed ventures that replace human workers with robots.Elon Musk, a top donor and adviser to Trump, has touted humanoid robots as a future growth area for electric-carmaker Tesla. "You can produce any product,” Musk said of the robots’ potential capacity during a February interview with Dubai's World Governments Summit.Amazon founder Jeff Bezos, who Trump last month called “terrific,” has invested in several advanced robotics firms.Bezos last year poured funds into Figure, a humanoid robot company that says its initial rollout will focus on manufacturers and warehouses, among other business applications. “We believe humanoids will revolutionize a variety of industries,” the company says on its website.Nvidia CEO Jensen Huang and OpenAI CEO Sam Altman – both of whom joined Trump on his recent trip to the Middle East – helmed their respective companies as each invested in Figure. OpenAI ended its partnership with Figure last year.“Trump is talking about bringing back the jobs, and he’s not understanding the tension between that goal and automation, which the tech bros have enthusiasm for,” Harry Holzer, a professor of public policy at Georgetown University and a former chief economist at the U.S. Department of Labor, told ABC News. “There’s a fundamental conflict between those goals.”MORE: Trump wants Apple to make iPhones in the US. Will it ever happen?Musk did not immediately respond to ABC News’ request for comment made through Musk-owned firm SpaceX. Neither Bezos, Huang nor Altman responded to ABC News’ request.Speaking at a conference in April, Huang said the onset of artificial intelligence would fuel "new types of factories," which in turn would create jobs in construction and steelmaking, as well as in trades such as plumbing and electricity.Even more, Huang said, AI is set to trigger a surge in productivity at companies that adopt the new technology, allowing them to add employees as the firms increase output and revenue."New jobs will be created, some jobs will be lost, every job will be changed," Huang said. "Remember, it's not AI that's going to take your job. It's not AI that's going to destroy your company. It's the company and the person who uses AI that's going to take your job. And so that's something to internalize."Even after a rollback of some levies, consumers face the highest overall average effective tariff rate since 1934, the Yale Budget Lab found earlier this month.A key reason for the tariffs, White House officials say: Reshoring factories and rejuvenating employment in the manufacturing industry.Commerce Secretary Howard Lutnick said this month in an interview with Fox News that Trump's vision for ushering in a "golden age" for America involved enticing manufacturers to open factories and build in the United States."We're going to have huge jobs in manufacturing. You've heard the president talk about trillions and trillions of factories being built in America," he said in the interview on May 11.In response to ABC News' request for comment, White House Spokesperson Kush Desai said "the importance of President Trump’s push to reinvigorate American industry goes beyond creating good-paying jobs for everyday Americans.""Supply chain shocks of critical pharmaceuticals, medical equipment, and semiconductors during the COVID era prove that America cannot rely on foreign imports. The Trump administration remains committed to reshoring manufacturing that’s critical to our national and economic security with a multifaceted approach of tariffs, tax cuts, rapid deregulation, and domestic energy production," Desai added.The share of U.S. workers in manufacturing has plummeted for decades. Roughly 8% of U.S. workers currently hold positions in manufacturing, which marks a steep decline from about a quarter of all employees as recently as 1970.Researchers attribute such decline to overlapping trends, including the offshoring of manufacturing to low-wage markets overseas and the adoption of labor-saving technology throughout the sector.Long before current advances, automation significantly increased productivity in U.S. factories, meaning the same number of workers could produce many more goods, researchers at Ball State University found in 2015. As a result, they said, manufacturing employment stagnated for decades even as output climbed.Popular Reads“Automation is something we’ve seen for a long time,” Philipp Kircher, a professor of industrial and labor relations at Cornell University, told ABC News.CEO of Meta and Facebook Mark Zuckerberg, Lauren Sanchez, Amazon founder Jeff Bezos, Google CEO Sundar Pichai and Tesla and SpaceX CEO Elon Musk attend the inauguration ceremony of Donald Trump in Washington, D.C., on Jan. 20, 2025.Julia Demaree Nikhinson, Pool via AFP via Getty Images, FILESome of Trump’s tech allies have backed firms that seek to further automate manufacturing, touting a new wave of artificial-intelligence equipped robots as a replacement for some workers and salve for labor shortages.Robotics outfit Vicarious boasts $250 million in investments from a set of backers that includes Bezos, Musk and Meta CEO Mark Zuckerberg – all of whom flanked Trump during his inauguration.On a webpage displaying photos of robots for use in warehouse settings, Vicarious tells potential clients that the products can “reduce both your costs and person-hour needs.”In 2022, Vicarious was acquired by Alphabet-backed robotics software firm Intrinsic. Alphabet CEO Sundar Pichai also sat alongside tech leaders at Trump’s inauguration.Alphabet did not respond to ABC News' request for comment. Meta declined to comment.Yong Suk Lee, a professor of economics and technology at the University of Notre Dame, described the views on automation among Trump’s tech allies and some of his trade advisers as “opposed.”The tech position, Lee said, would likely win out, even if some firms do open plants in the U.S.“If you want to reshore, are you going to pay the same wages as Vietnam? Probably not,” Lee said. “Companies are faced with higher labor costs. In that case, they’ll probably automate.”Discordant views among some tech leaders and White House officials surfaced in April, when Musk sharply criticized tariff-advocate Peter Navarro, Trump’s senior counselor for trade and manufacturing. Navarro, Musk said, is “truly a moron.”In an interview with CNBC, Navarro responded, saying Musk "isn't a car manufacturer — he's a car assembler.”MORE: Target CEO says tariffs risk 'massive' costs, but price hikes a 'last resort'To be sure, analysts said, automation in manufacturing would likely continue regardless of support from Trump’s tech allies, since producers are locked in a competition to lower costs and increase output. The precise outlook for manufacturing employment is unclear, they added, since additional technology may add jobs for those maintaining and optimizing the machinery.“Whether it’s the companies that currently support the U.S. president or not, somebody would be doing this innovation, maybe slightly slower,” Kircher said.Even at current employment levels, a labor shortage bedevils U.S. manufacturers. Roughly one of every five U.S. factories that failed to produce at full capacity cited a shortage of workers, Jason Miller, a professor of supply chain management at Michigan State University, found in a January study analyzing government data.Agility Robots, an Amazon-backed firm building humanoid robots, identifies the current push for rejuvenated U.S. manufacturing as an opportunity for greater adoption of technology.“Manufacturing companies are seeing a massive reshoring movement spanning various industries,” Agility Robots says on its website. “Adding a humanoid robot to your manufacturing facility is a great way to stay on the leading edge of automation.”In response to ABC News' request for comment, an Amazon spokesperson pointed to previous remarks about robotics made by a company executive."Our goal is to ensure these systems improve safety and productivity. Technology should be used to help us retain and grow our talent through skill development and reimagining how we make our workplace better, both in productivity and safety. If we do this well, we’re certain to always innovate for our customers," Tye Brady, chief technologist at Amazon Robotics, said in a September blog post.Amazon has "created more U.S. jobs in the last decade than any other company," Amazon said this month.

May 21, 202510 min readSleep Better with New Drugs, Select Cannabinoids and Wearable DevicesDrugs that target wakefulness, molecules in cannabis and wearable devices that modulate brain activity could help people with insomniaBy Rachel Nuwer carlofranco/Getty ImagesThis Nature Outlook is editorially independent, produced with financial support from Avadel.Miranda cannot remember a time in her life when she did not have insomnia. The 23 year old, who asked for her last name to be withheld, started struggling with sleep when she was a child. As she’s grown older, it’s only become worse. She takes “a myriad of medications” each night, she says, but usually still cannot fall asleep until the early hours of the morning. “I can’t get up and be functional until halfway through the day,” she says. She had to drop out of university because she couldn’t attend classes, and she can’t hold down a job. Her insomnia exacerbates other medical conditions as well, including migraines and the pain condition fibromyalgia. “It’s hugely debilitating,” she says. “It affects everything.”In the United States, about 12% of adults have been diagnosed with chronic insomnia — when a person struggles to sleep for more than three nights each week for at least three months, and experiences daytime distress as a result. Research suggests that the worldwide figure is 10–30%. It also often co-occurs with and creates a vicious cycle with other conditions, including chronic pain, depression and anxiety.On supporting science journalismIf you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today.Fortunately for Miranda and millions of others with chronic insomnia, new treatments are arriving. The emergence of a class of pharmaceuticals that induces sleep through a different brain pathway from existing drugs is a welcome development, and molecules in cannabis and specialized medical devices to promote sleep are also showing potential as sleep aids. Soon, those struggling with sleep could have a range of new options available to help.Imperfect solutionsCognitive behavioural therapy for insomnia (CBT-I) is usually the recommended first treatment. This specialized talking therapy focuses on establishing healthy sleep behaviours and addressing thoughts that can interfere with sleep. But CBT-I is not covered by all health-care insurance plans in the United States. In the United Kingdom and parts of Europe, public health-care systems usually provide it, but waiting times can be long. This is because, around the world, there is a limited availability of therapists, says Andrew Krystal, a psychiatrist at the University of California, San Francisco. “We keep hiring new people, but almost immediately their schedules are completely filled and the wait list is a year.”CBT-I also doesn’t work for everyone. Miranda has tried it and has received conventional talking therapy for over a decade, with limited success. “It only helps so much,” she says.Pharmacological interventions are the next line of defence, Krystal says. Benzodiazepines and a class of medicines called Z-drugs, which include zolpidem (Ambien), are among the most prescribed insomnia medications. These sedative hypnotics enhance the effects of the neurotransmitter GABA, thereby dampening brain activity. They also reduce anxiety. But they can create a hangover effect and increase the risk of falls in older people. These drugs also have the potential for misuse and can cause dependence. Some studies have even found an association between long-term use of Z-drugs and benzodiazepines and an increased risk of death.Miranda tried Ambien, but says that she quickly became chemically dependent. She eventually weaned herself off it and switched to benzodiazepines, but she began developing a tolerance to them, too — she once wound up in hospital with withdrawal symptoms after she tried to cut back on her dosage. “They’re horrible drugs to be on,” she says. But she cannot fall asleep without them. Each night, she now takes two benzodiazepines, as well as gabapentin, an anticonvulsant medication that is sometimes given off-label for insomnia.Physicians frequently provide other off-label prescriptions for insomnia, including trazodone, which is approved for depression. Over-the-counter products such as antihistamines are also used for sleeplessness. None are ideal, however, because they have not been evaluated as sleep aids, says Emmanuel Mignot, a sleep-medicine researcher at Stanford University in California.Miranda has experience with many of these products. When she first developed chronic insomnia as a child, her paediatrician recommended melatonin, which is available without a prescription in the United States. It helped her fall asleep, but it did not keep her asleep. During her teenage years, different neurologists prescribed off-label antidepressants and other mood medications, including trazodone and mirtazapine. But they came with what she calls “torturous” side effects: she felt constantly anxious and exhausted during the day, and her memory became “incredibly foggy”.Blocking wakefulnessMignot was studying narcolepsy, a chronic disorder that affects sleep–wake cycles and causes people to fall asleep suddenly, when he inadvertently helped to pave the way towards the latest means of treating insomnia. He discovered that dogs with narcolepsy have a genetic mutation that affects one of two receptors used by the neurotransmitter orexin, the primary role of which was initially thought to be the regulation of appetite. Mignot then found that people with narcolepsy lack orexin, confirming the chemical’s main job: promoting wakefulness. If drugs could be developed to prevent orexin from binding to its receptors, Mignot thought, then people with insomnia would become “narcoleptic for one night”.In 2007, researchers at the pharmaceutical firm Actelion (part of which is now Idorsia Pharmaceuticals in Switzerland) showed that blocking orexin’s two receptors induced sleep in rats, dogs and people. In 2014, the biopharmaceutical company Merck, received US Food and Drug Administration (FDA) approval for the first dual orexin receptor antagonist (DORA) drug, suvorexant (Belsomra). In 2019, another DORA drug — lemborexant (Dayvigo) — was approved, followed, in 2022, by daridorexant (Quviviq).Compared with benzodiazepines and Z-drugs, which inhibit activity all over the brain, DORA drugs affect only the neurons activated by orexins (see ‘Blocking wakefulness’). “The beauty of it is it does nothing but block the stimulation of wakefulness,” says neurologist Joe Herring, who heads neuroscience clinical research at Merck in Rahway, New Jersey. “It’s a physiologically better way to promote sleep.”Alisdair Macdonald/NatureDaridorexant is the only DORA drug for which data are available about daytime functioning, says Antonio Olivieri, chief medical officer at Idorsia, which produces daridorexant. In clinical trials, Idorsia showed that, compared with those given a placebo, people who received daridorexant experienced significant improvements in daytime insomnia symptoms the following day. Data reported in the approvals database of the FDA also indicate that daridorexant has the lowest fatigue and drowsiness scores of the three DORA drugs, possibly because it leaves the body the quickest.So far, there have been no one-to-one comparisons of DORA drugs. “Ideally, you’d have direct evidence of how those drugs compare to each other,” says Daniel Buysse, a sleep scientist at the University of Pittsburgh School of Medicine in Pennsylvania. “But we rarely have such evidence, so instead, we have to rely on statistical techniques that allow you to make indirect comparisons.” It’s also difficult to say definitively how DORA drugs compare with older treatments for insomnia, but Buysse says that drug registration trials suggest that DORA drugs have fewer adverse cognitive or hangover effects compared with benzodiazepines and Z-drugs, as well as less potential for dependence and misuse. The European Insomnia Guideline 2023 placed daridorexant as the next recommended insomnia treatment after CBT-I.The main drawback to DORA drugs, Buysse says, is not medical but financial: their high cost keeps them out of reach of many people who could benefit from them. “There are many patients I would like to prescribe these drugs for, but I know in order for them to get one of these medications we’ll have to go through trials of several other drugs before the request will be considered,” Buysse says. DORA drugs are also available only in a few countries, so far.Given her long history of insomnia, Miranda was given a prescription for suvorexant. Her psychiatrist recommended the drug to her about a year ago. “I was really sceptical that an anti-wakefulness drug would be any different to a pro-sleep drug,” she says. But she quickly felt the difference, and has now come to see the drug as “a saviour”. Without the drug, she says, “I’d probably be on a much higher benzodiazepine dose than I am.” She hopes her suvorexant dose can continue to increase, so that some of her other medications can be reduced.Expanding availabilityOther drugs that target the orexin system are in the clinical pipeline. Seltorexant, for example, is being developed by the US pharmaceutical firm Johnson & Johnson for people with both major depressive disorder and insomnia. Around 70% of people with depression have insomnia, so having a medication that treats both of those disorders “has the potential to fill an important gap”, says Krystal, who has consulted for Johnson & Johnson on the drug. In a phase III trial, participants who took the drug experienced meaningful improvement in both sleep and depressive symptoms, with an antidepressant effect that seemed to be independent of the participants getting better sleep. Seltorexant might have an antidepressant effect because it is designed to block only one of the two types of orexin receptor, Krystal adds, whereas other DORA drugs block both receptor types.Investigations of already-approved DORA drugs are also expanding into other populations. Merck has sponsored investigator-led studies of suvorexant in people with insomnia as well as depression or substance-use disorders, and Idorsia is sponsoring studies of daridorexant’s safety and efficacy in sub-groups of people who have insomnia and other conditions.In 2020, suvorexant became the first medication to be approved for treating sleep disorders in people with Alzheimer’s disease. Insomnia is often a precursor to and co-morbid with Alzheimer’s, and the disease seems to manifest differently in people with the condition. In one study comparing older people with insomnia with those with both insomnia and Alzheimer’s, people with both conditions had a number of extra changes to their sleep patterns, including less time spent in deep sleep — sometimes called slow-wave sleep because that describes the pattern of the brain’s electrical activity during these intervals. Sleep problems in people with Alzheimer’s also seem to have a causal role in increasing levels of toxic substances in the brains of those individuals. Preliminary data suggest that suvorexant could also help to reduce toxic brain proteins. The results of a follow-up study testing that finding are expected in 2026.In the weedsSleeplessness is already among the most common conditions for the medicinal use of the drug cannabis. Miranda, for example, supplements her nightly pharmaceutical regimen with a cannabis tincture that contains a few of the plant’s 100-plus cannabinoids (she lives in a state where cannabis use is legal). “It’s definitely a key player in my sleep-medication arsenal,” she says.Yet, scientifically, little is known about which cannabinoids — if any — promote sleep, and what a safe and effective dose is. “Tens of millions of people around the world are probably using cannabinoids for insomnia, but we have very little good-quality evidence to support that,” says Iain McGregor, director of the Lambert Initiative for Cannabinoid Therapeutics at the University of Sydney in Australia.McGregor is investigating cannabinol (CBN), a molecule that develops in cannabis as the psychoactive component tetrahydrocannabinol (THC) oxidizes. His group reported that CBN increased sleep in rats to a similar degree as zolpidem, but without the drug’s known negative side effect of suppressing rapid-eye-movement sleep. Unpublished data of a single-night trial with 20 people with insomnia disorder show that people fell asleep 7 minutes faster after taking 300 milligrams of CBN compared with those taking a placebo; participants also reported subjective improvements in sleep and mood. Although 7 minutes “doesn’t sound like a lot”, it is on a par with what benzodiazepines and Z-drugs typically accomplish, says Camilla Hoyos, a sleep researcher at the Woolcock Institute of Medical Research in Sydney, who led the work. McGregor, Hoyos and their colleagues are aiming to follow up the work with a large, community-based trial in which people with insomnia take either CBN or a placebo for six weeks at home.As for cannabidiol (CBD) and THC — the most well-known cannabinoids — the prospects for efficacy against insomnia are doubtful, at least for the doses used in trials so far. Several small studies have failed to find a sleep benefit from taking CBD. In one experiment, researchers observed that participants in a study who received 10 milligrams of THC and 200 milligrams of CBD actually slept for 25 minutes less compared with when they received a placebo. Several other company-sponsored trials of low-dose CBD for insomnia were not published, McGregor adds, because they found no significant improvement. “It’s been one failure after the next,” he says.Insomnia’s new frontiersThe search for more effective insomnia treatments continues in other realms, as well. Some research groups are experimenting with different receptors that they hope could lead to new classes of drugs. Gabriella Gobbi, a clinical psychiatrist and research neuroscientist at McGill University in Montreal, Canada, for example, has homed in on one of the brain’s two melatonin receptors, MT2. “We want to find an alternative mechanism without any addiction liability and with fewer side effects, especially for use in children and elderly people,” she says. A molecule that the team developed that binds to MT2 increased the time that rats spent in deep sleep by 30%. Gobbi aims to launch clinical trials in the next two to three years.A few companies and health systems, including the US Department of Veterans Affairs and the Cleveland Clinic in Ohio, have also created or are developing digital platforms for delivering CBT-I. These apps take users through regimens that are tailored to their symptoms. SleepioRx, for example, is a 90-day digital programme that has been evaluated in more than two dozen clinical trials and has showed efficacy as high as 76%. This includes helping people to fall asleep faster, sleep better throughout the night and feel better the next day. In August 2024, the programme, developed by Big Health in San Francisco, California, received FDA clearance. A 2024 meta-analysis of 15 studies that compare in-person and electronically delivered CBT-I concluded that the two approaches were equally effective.Uptake among physicians has been slow so far, Krystal says. But once practitioners catch on, he adds, “I can imagine a world where you have digital care as your first stop, and if that’s not successful, you see a therapist.”Some studies suggest that insomnia can stem from a high level of underlying brain activity during sleep. This raises the question of whether reducing this activity could treat insomnia, says Ruth Benca, a psychiatrist at Wake Forest School of Medicine in North Carolina. Companies and academic research groups are beginning to test this proposition with wearable devices that use auditory tones or mild electrical stimulation to increase slow-wave activity in the brain. Some devices are already on the market, and evidence suggests that they can increase the duration of deep sleep. Last June, for example, researchers at Elemind Technologies in Cambridge, Massachusetts, confirmed that auditory stimuli delivered in sync with specific brain-wave rhythms generated in a headband allowed people who usually struggle for more than 30 minutes to fall asleep to shave an average of 10.5 minutes off that time.In the coming years, according to Benca, researchers hope to learn enough about insomnia’s causes and treatments to be able to recommend personalized therapies based on an individual’s specific demographics, genetics and co-morbidities. These are the frontiers people are working at, she says.Even after a lifetime of struggling to find safe and effective help, Miranda says that she still holds out hope that better treatments for insomnia are on the horizon. “I can’t be on these medications forever,” she says. “They’re going to take years off my life.”

New print jobs How 3D printing is personalizing health care Prosthetics are becoming increasing affordable and accessible thanks to 3D printers. Anne Schmitz and Daniel Freedman, The Conversation – May 20, 2025 5:43 pm | 20 German Chancellor Olaf Scholz shakes hands with the prosthetic hand of a worker of the German med-tech company Ottobock. Credit: JOHN MACDOUGALL/AFP via Getty Images German Chancellor Olaf Scholz shakes hands with the prosthetic hand of a worker of the German med-tech company Ottobock. Credit: JOHN MACDOUGALL/AFP via Getty Images Story text Size Small Standard Large Width * Standard Wide Links Standard Orange * Subscribers only   Learn more Three-dimensional printing is transforming medical care, letting the health care field shift from mass-produced solutions to customized treatments tailored to each patient’s needs. For instance, researchers are developing 3D-printed prosthetic hands specifically designed for children, made with lightweight materials and adaptable control systems. These continuing advancements in 3D-printed prosthetics demonstrate their increasing affordability and accessibility. Success stories like this one in personalized prosthetics highlight the benefits of 3D printing, in which a model of an object produced with computer-aided design software is transferred to a 3D printer and constructed layer by layer. We are a biomedical engineer and a chemist who work with 3D printing. We study how this rapidly evolving technology provides new options not just for prosthetics but for implants, surgical planning, drug manufacturing, and other health care needs. The ability of 3D printing to make precisely shaped objects in a wide range of materials has led to, for example, custom replacement joints and custom-dosage, multidrug pills. Better body parts Three-dimensional printing in health care started in the 1980s with scientists using technologies such as stereolithography to create prototypes layer by layer. Stereolithography uses a computer-controlled laser beam to solidify a liquid material into specific 3D shapes. The medical field quickly saw the potential of this technology to create implants and prosthetics designed specifically for each patient. One of the first applications was creating tissue scaffolds, which are structures that support cell growth. Researchers at Boston Children’s Hospital combined these scaffolds with patients’ own cells to build replacement bladders. The patients remained healthy for years after receiving their implants, demonstrating that 3D-printed structures could become durable body parts. As technology progressed, the focus shifted to bioprinting, which uses living cells to create working anatomical structures. In 2013, Organovo created the world’s first 3D-bioprinted liver tissue, opening up exciting possibilities for creating organs and tissues for transplantation. But while significant advances have been made in bioprinting, creating full, functional organs such as livers for transplantation remains experimental. Current research focuses on developing smaller, simpler tissues and refining bioprinting techniques to improve cell viability and functionality. These efforts aim to bridge the gap between laboratory success and clinical application, with the ultimate goal of providing viable organ replacements for patients in need. Three-dimensional printing already has revolutionized the creation of prosthetics. It allows prosthetics makers to produce affordable custom-made devices that fit the patient perfectly. They can tailor prosthetic hands and limbs to each individual and easily replace them as a child grows. Three-dimensionally printed implants, such as hip replacements and spine implants, offer a more precise fit, which can improve how well they integrate with the body. Traditional implants often come only in standard shapes and sizes. Some patients have received custom titanium facial implants after accidents. Others had portions of their skulls replaced with 3D-printed implants. Additionally, 3D printing is making significant strides in dentistry. Companies such as Invisalign use 3D printing to create custom-fit aligners for teeth straightening, demonstrating the ability to personalize dental care. Scientists are also exploring new materials for 3D printing, such as self-healing bioglass that might replace damaged cartilage. Moreover, researchers are developing 4D printing, which creates objects that can change shape over time, potentially leading to medical devices that can adapt to the body’s needs. For example, researchers are working on 3D-printed stents that can respond to changes in blood flow. These stents are designed to expand or contract as needed, reducing the risk of blockage and improving long-term patient outcomes. Simulating surgeries Three-dimensionally printed anatomical models often help surgeons understand complex cases and improve surgical outcomes. These models, created from medical images such as X-rays and CT scans, allow surgeons to practice procedures before operating. For instance, a 3D-printed model of a child’s heart enables surgeons to simulate complex surgeries. This approach can lead to shorter operating times, fewer complications, and lower costs. Personalized pharmaceuticals In the pharmaceutical industry, drugmakers can three-dimensionally print personalized drug dosages and delivery systems. The ability to precisely layer each component of a drug means that they can make medicines with the exact dose needed for each patient. The 3D-printed anti-epileptic drug Spritam was approved by the Food and Drug Administration in 2015 to deliver very high dosages of its active ingredient. Drug production systems that use 3D printing are finding homes outside pharmaceutical factories. The drugs potentially can be made and delivered by community pharmacies. Hospitals are starting to use 3D printing to make medicine on-site, allowing for personalized treatment plans based on factors such as the patient’s age and health. However, it’s important to note that regulations for 3D-printed drugs are still being developed. One concern is that postprinting processing may affect the stability of drug ingredients. It’s also important to establish clear guidelines and decide where 3D printing should take place – whether in pharmacies, hospitals or even at home. Additionally, pharmacists will need rigorous training in these new systems. Printing for the future Despite the extraordinarily rapid progress overall in 3D printing for health care, major challenges and opportunities remain. Among them is the need to develop better ways to ensure the quality and safety of 3D-printed medical products. Affordability and accessibility also remain significant concerns. Long-term safety concerns regarding implant materials, such as potential biocompatibility issues and the release of nanoparticles, require rigorous testing and validation. While 3D printing has the potential to reduce manufacturing costs, the initial investment in equipment and materials can be a barrier for many health care providers and patients, especially in underserved communities. Furthermore, the lack of standardized workflows and trained personnel can limit the widespread adoption of 3D printing in clinical settings, hindering access for those who could benefit most. On the bright side, artificial intelligence techniques that can effectively leverage vast amounts of highly detailed medical data are likely to prove critical in developing improved 3D-printed medical products. Specifically, AI algorithms can analyze patient-specific data to optimize the design and fabrication of 3D-printed implants and prosthetics. For instance, implant makers can use AI-driven image analysis to create highly accurate 3D models from CT scans and MRIs that they can use to design customized implants. Furthermore, machine learning algorithms can predict the long-term performance and potential failure points of 3D-printed prosthetics, allowing prosthetics designers to optimize for improved durability and patient safety. Three-dimensional printing continues to break boundaries, including the boundary of the body itself. Researchers at the California Institute of Technology have developed a technique that uses ultrasound to turn a liquid injected into the body into a gel in 3D shapes. The method could be used one day for delivering drugs or replacing tissue. Overall, the field is moving quickly toward personalized treatment plans that are closely adapted to each patient’s unique needs and preferences, made possible by the precision and flexibility of 3D printing. Anne Schmitz, Associate Professor of Engineering, University of Wisconsin-Stout and Daniel Freedman, Dean of the College of Science, Technology, Engineering, Mathematics & Management, University of Wisconsin-Stout. This article is republished from The Conversation under a Creative Commons license. Read the original article. Anne Schmitz and Daniel Freedman, The Conversation The Conversation is an independent source of news and views, sourced from the academic and research community. Our team of editors work with these experts to share their knowledge with the wider public. Our aim is to allow for better understanding of current affairs and complex issues, and hopefully improve the quality of public discourse on them. 20 Comments

Regeneron is acquiring "substantially all" of 23andMe's assets for $256 million following a bankruptcy auction.

Image by Getty / FuturismGeneticsYour DNA results are in — and they're 100 percent the property of a pharmaceutical manufacturer.American biotech company Regeneron Pharmaceuticals announced today that it's buying 23andMe, the bankrupt consumer-genomics company that sold take-home DNA kits. Regeneron is to pay $256 million in cash to acquire "substantially all" of 23andMe's assets, including its massive biobank of around 15 million customer genetic samples and data.Put simply, the genetic information of millions is now in the hands of a drugmaker seeking to mine it to make new therapies,  per the Washington Post, which could be a data privacy nightmare in the making.Said samples were willingly given by consumers in exchange for 23andMe to decode their DNA, a process that offered people a fascinating glimpse into their genetic makeup and family histories. That kind of biometric data is both wildly valuable and widely sought-after, so when 23andMe went belly-up financially, its trove of genetic information quickly drew attention as a lucrative asset. That realization immediately sparked concerns among data privacy experts, who warned that a sale of 23andMe data meant that the genetic information of customers, not to mention information about customers' close and distant relatives, was up for grabs to the highest bidder.In its press release, Regeneron said it "intends" to honor 23andMe's existing privacy practices. Regeneron cofounder and president George Yancopoulos, meanwhile, issued a statement emphasizing the drugmaker's "deep experience with large-scale data management, having worked with collaborators around the world to link deidentified DNA sequences from nearly three million consented participants to electronic health records, safely and securely enabling future medical advances.""We believe we can help 23andMe deliver and build upon its mission to help those interested in learning about their own DNA and how to improve their personal health," Yancopoulos' statement continued, "while furthering Regeneron's efforts to use large-scale genetics research to improve the way society treats and prevents illness overall."That said, Regeneron isn't just a research lab. It sells the drugs it creates, and should genomic data gleaned from the historic sale lead to the creation and eventual monetization of medications, it raises questions around whether consumers will ever be compensated for their contributions.23andMe board chair Mark Jensen, for his part, said in a statement that the deal "maximizes the value of the business and enables the mission of 23andMe to live on, while maintaining critical protections around customer privacy, choice, and consent with respect to their genetic data."More on 23andMe: 23andMe Is Selling All Your Data, in Largest Sale of Genomes in HistoryShare This Article

Microsoft Word’s spell check can already suggest words in real time, but imagine an “idea check” future in which AI suggests ideas on the fly as users type. This is how Microsoft is evolving Copilot — as an AI assistant predicting ideas in real time by tapping into unique corporate and user data. That’s an idea the company shared for Microsoft 365 as generative AI technology sinks deeper into the guts of the software. Specifically, Microsoft on Monday released a feature called Copilot Tuning, which will allow enterprises to deploy specialized AI models and agents that are fine-tuned to company operations and data. The feature was announced at Microsoft’s Build developer show being held this week. With Copilot Tuning, companies can train models on their own data and deploy AI agents that make use of their unique terms, context, and processes, said Jason Henderson, corporate vice president of Microsoft 365 product management, in an interview with Computerworld. “AI is going to have to … integrate the knowledge from your work into your specific Copilot so it can customize documents and workflows to the way your company works,” Henderson said. The larger goal behind Tuning is to create an “enterprise brain” that is a digital representation of an organization’s unique way of handling information, processing it and making decisions. That is key to creating Copilots that can recommend ideas, Henderson said. The ability to fine-tune AI to internal data changes the way model reasons and responds. That, in turn, changes how employees create documents and generate summaries. Henderson gave the example of a longstanding law firm with more than 100 years of institutional knowledge and precedents. The partners are retiring and taking their knowledge with them. “What they’re really interested in is fine-tuning into these models all these legal agreements that they have built over many, many years. And then being able to create new ones based on that learning,” Henderson said. Microsoft Copilot launched in 2023 providing generic responses from genAI large language models (LLMs), notably OpenAI’s GPT series. About 70% of Fortune 500 companies are now using Copilot in some form, according to Microsoft. Although LLM-based chatbots such as Anthropic’s Claude, Google’s Gemini and especially OpenAI’s ChatGPT remain popular, some companies are shifting to smaller reasoning models that are fine-tuned to domain data, finding the smaller models cheaper, faster, more customizable, and more secure. Microsoft says Copilot Tuning is the starting point to creating hyper-personalized features, such as suggesting ideas in real time as a person writes a document in Word. “I can think of this as a spell check of the future where it knows the words that your company uses. It’s going to predict based on what it knows about your company. It might be one thing in manufacturing versus in pharmaceuticals. It’s trying to help you get one step ahead by bringing to your fingertips what you need,” Henderson said. Security is an important part of Copilot Tuning, and the data is usually pulled and referenced from Microsoft SharePoint, which monitors access to files. Microsoft is creating a chain of custody and security from documents to the model. “We’re starting with SharePoint, but with connectors, we can bring in many, many different systems,” Henderson said. Google, Anthropic, and OpenAI all offer ways to integrate enterprise data into LLMs as well.  The new Copilot Tuning offering doesn’t require data scientists or coders, and it has a point-and-click interface within Copilot Studio. It can be used by regular employees who may think, “hey, I want to make my department’s life easier,” Henderson said. Microsoft is also creating “recipes” that are targeted at generating documents and summaries, or for data analysis and accounting tasks. “We’re going to identify which models best handle those recipes, doing a lot of experimentation to pick the right model for each particular recipe. Over the next six months, we’ll continue to build out more recipes as we identify durable problem spaces that companies are interested in addressing with Copilot Tuning,” Henderson said. The Copilot Tuning functionality will begin rolling out to Microsoft 365 Copilot customers next month as part of its “Early Adopter Program.” Microsoft’s Copilot Wave 2 spring release — which includes a new Copilot app with new search, summarization, and personalization functionality — is now generally available.